1-3 of 3
Uwe Pichlmeier
Close
Sort by
Journal Articles

Allogeneic Stem Cell Transplantation after Conditioning with Treosulfan, Etoposide and Cyclophosphamide for Patients with Acute Lymphoblastic Leukemia (ALL) Not Eligible for TBI-Containing Regimens: A Phase II-Study on Behalf of the German ALL Study Group (GMALL) and the German Cooperative Transplant Study Group

Nicolaus Kröger, MD, Martin Bornhäuser, MD, Matthias Stelljes, Uwe Pichlmeier, Christoph Schmid, Renate Arnold, Gesine Bug, Ralf Georg Meyer, MD, Wolfgang A. Bethge, MD, Guido Kobbe, MD, Dietrich Beelen, MD
Journal: Blood
Blood (2014) 124 (21): 2461.
https://doi.org/10.1182/blood.V124.21.2461.2461
Published: 2014
Journal Articles

Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial

Clinical Trials & Observations
Rob Pieters, Inge Appel, Hans-Juergen Kuehnel, Iris Tetzlaff-Fohr, Uwe Pichlmeier, Inekee van der Vaart, Eline Visser, Rolinda Stigter
Journal: Blood
Blood (2008) 112 (13): 4832–4838.
https://doi.org/10.1182/blood-2008-04-149443
Published: 2008
Journal Articles

Allogeneic Blood Stem Cell Transplantation in Patients with Hematologic Diseases after Conditioning with Treosulfan and Fludarabine.

Jochen Casper, PD. Dr.Med., Stefan Wilhelm, Dr.Med., Beate Steiner, Dr.Med., Daniel Wolff, Dr.Med., Norbert Grobe, Dr.Med., Detlev Haehling, Dr.Med., Gernot Hartung, PD. Dr.Med., Inken Hilgendorf, Dr.Med., Andreas Lueck, Dr.Med., Christian Junghanss, Christoph Kahl, Dr.Med., Uwe Pichlmeier, PD. Dr.rer.Nat., Mathias Freund, Dr. Med.
Journal: Blood
Blood (2005) 106 (11): 2744.
https://doi.org/10.1182/blood.V106.11.2744.2744
Published: 2005